Pfizer Reports Third-Quarter 2011 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today reported financial results for third-quarter 2011. Third-quarter 2011 revenues were $17.2 billion, an increase of 7% compared with the year-ago quarter, which reflects operational growth of $247 million, or 1%, and the favorable impact of foreign exchange of $951 million, or 6%.
Daiichi Sankyo Establishes New Vaccine Research Unit in Japan
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has established a new Japanese vaccine research unit to be located in its Kasai R&D Center (Edogawa-ku, Tokyo).
Pfizer Completes Acquisition Of Icagen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.
Shire continued strong product sales performance in Q3
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011.
After a good third quarter: Bayer confirms Group outlook
- Details
- Category: Bayer
Sales of the Bayer Group rose by 1.0 percent in the third quarter to EUR 8,670 million (Q3 2010: EUR 8,581 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 4.8 percent.
Bristol-Myers Squibb Delivers Strong Third Quarter
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has announced double-digit net sales growth in a quarter highlighted by important new data on ELIQUIS ® for stroke prevention in patients with atrial fibrillation and continued investment in external innovation with several strategic transactions.
AstraZeneca Third Quarter Results
- Details
- Category: AstraZeneca
AstraZeneca's Revenue in the third quarter was down 2 percent at CER, but was up 4 percent on an actual basis as a result of the positive impact of exchange rate movements. Revenue performance was impacted by government price interventions and the loss of more than $350 million in revenue to generic competition.
More Pharma News ...
- Amgen's Third Quarter Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent
- GSK delivers strong Q3 performance with underlying sales growth
- Merck Total Revenues Increase by 4% to € 2.5 Billion
- Novartis achieves strong third quarter financial performance and pipeline progress
- Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
- AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
- Lilly Reports Third-Quarter 2011 Results